American Physiological Society, Journal of Applied Physiology, 3(130), p. 617-626, 2021
DOI: 10.1152/japplphysiol.00553.2020
Full text: Unavailable
Here, we show that daily oral treatment with selective β2-agonist salbutamol induces muscle fiber isoform transition from myosin-heavy-chain (MHC)-I toward MHCIIa and augments hypertrophy of MHCIIa fibers during a period of resistance training. Compared with placebo, salbutamol enhanced sprint mean power output, whereas peak power output and measures of muscle strength increased similarly during the resistance training period despite augmented hypertrophy with salbutamol. Thus, salbutamol is a muscle anabolic drug that can enhance sprint ability adaptations to resistance training.